Gain Therapeutics Files 8-K
Ticker: GANX · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1819411
| Field | Detail |
|---|---|
| Company | Gain Therapeutics, Inc. (GANX) |
| Form Type | 8-K |
| Filed Date | Feb 6, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
TL;DR
Gain Therapeutics filed a standard 8-K, no major news.
AI Summary
Gain Therapeutics, Inc. filed an 8-K on February 6, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by Gain Therapeutics, Inc. to the SEC, without disclosing new material events.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any new risks or significant events.
Key Players & Entities
- Gain Therapeutics, Inc. (company) — Registrant
- February 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-40237 (identifier) — Commission File Number
- 85-1726410 (identifier) — IRS Employer Identification No.
- 4800 Montgomery Lane , Suite 220, Bethesda , Maryland 20814 (address) — Principal Executive Offices
- ( 301 ) 500-1556 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is February 6, 2025.
In which state is Gain Therapeutics, Inc. incorporated?
Gain Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address of Gain Therapeutics, Inc.?
The principal executive office address is 4800 Montgomery Lane, Suite 220, Bethesda, Maryland 20814.
Does this filing disclose any new material events or financial results?
This filing does not appear to disclose any new material events or specific financial results beyond standard reporting requirements.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-02-06 16:50:25
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share GANX The Nasdaq
Filing Documents
- tm255679d1_8k.htm (8-K) — 26KB
- tm255679d1_ex99-1.htm (EX-99.1) — 18KB
- tm255679d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-25-010148.txt ( ) — 228KB
- ganx-20250206.xsd (EX-101.SCH) — 3KB
- ganx-20250206_lab.xml (EX-101.LAB) — 33KB
- ganx-20250206_pre.xml (EX-101.PRE) — 22KB
- tm255679d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On February 6, 2025, Gain Therapeutics, Inc. (the "Company") issued a press release providing an operational update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Gain Therapeutics, Inc., dated February 6, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 6, 2025 GAIN THERAPEUTICS, INC. By: /s/ Gene Mack Name: Gene Mack Title: Chief Executive Officer 2